anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an antisense nucleic acid glycosyl conjugate, a preparation method thereof and application thereof in liver cancer treatment. The antisense nucleic acid glycosyl conjugate is formed by covalent coupling of sugar molecules which are conjugated to the 5' end of antisense nucleic acid through a connecting arm. In vitro drug effect shows that the anti-tumor cell proliferation activity and the target gene silencing activity of each conjugate are equivalent to those of unconjugated antisense nucleic acid strands, and the activity of each conjugate is slightly better. Meanwhile, the drug uptake rate is improved after conjugation. In vivo experiments prove that the conjugate shows higher liver cancer inhibition activity, wherein Glu-CT102  MOE5  The effect is most obviousIt is well known that. In addition, the invention also preferably selects antisense nucleic acids PHN02 and PHN07 with the same target as CT102 but better in-vivo and in-vitro activity, and the PHN02 and PHN07 are further chemically modified  MOE5  Anti-tumor ability of CT102  MOE5  And (4) the equivalent. The invention lays a foundation for the wide clinical application of the anti-liver cancer antisense nucleic acid medicament, and has wide application prospect in the field of gene therapy.
PROBLEM TO BE SOLVED: To obtain a medicine for preventing and treating diabetes, etc., or for improving hepatic functions by using a specific protein obtained in a large amount at a relatively low cost. SOLUTION: This medicine for improving the hepatic functions contains betacellulin protein (hereinafter referred to as BTC protein) or its mutein as an active ingredient. The BTC protein is a protein factor produced by a pancreatic beta tumor cell originated from a transgenic mouse. The BTC protein is preferably a protein having e.g. a sequence of the formula. Especially, a protein having an amino acid sequence expressed by at least a sequence number selected from the sequence number group of 3, 4, 5 and 6 is preferable. A protein having an amino acid sequence of the sequence number 1 or 2 is further preferable. The mutein of the BTC protein is suitably a protein having an amino acid sequence obtained by deleting twelve or thirty amino acids from the N- terminal of the amino acid sequence expressed by the sequence number 1.  Further, the simultaneous employment of activin is further preferable.
Losartan potassium may be administered with other antihypertensive agents, and with or without food.

    Dosing must be individualized. The usual starting dose of Losartan potassium is 50 mg once daily, with 25 mg used in patients with possible depletion of intravascular volume (e.g., patients treated with diuretics) (see WARNINGS, Hypotension — Volume-Depleted Patients) and patients with a history of hepatic impairment (see  Error! Hyperlink reference not valid. ). Losartan potassium can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg.

If blood pressure is not controlled by Losartan potassium alone, a low dose of a diuretic may be added. Hydrochlorothiazide has been shown to have an additive effect (see Error! Hyperlink reference not valid.).

No initial dosage adjustment is necessary for elderly patients or for patients with renal impairment, including patients on dialysis.
The invention relates to the veterinary medicine, in particular to a method of treating the viral bacterial enteritis to calves. The proposed method includes watering of calves with a mixture containing I and II components. The I component comprises, vol. %: honey 5à15, 96? ethyl alcohol 30à40, virgin wax alkaline hydrolyzate 50à100 mg, the Ringer-Lokk solution the rest, and the II component comprises, vol. %: 10% solution of colostral immunoglobulins 5à15, 4à5% solution of sodium thiosulphate 2,5à10, 0,2% theotropine solution 0,1à0,3, the Ringer-Lokk solution the rest. At the same time, I and II components are taken in the quantity of 50à150 ml and 50à100 ml correspondingly and are diluted in 500 ml of boiled water, and watering of calves is carried out 2à3 times a day, during 2à3 days in starvation conditions.
GHD is the most common anterior pituitary abnormality after traumatic brain injury (TBI). It can occur as a result of either direct pituitary or indirect hypothalamic injury. Sports-related repetitive head trauma might induce pituitary dysfunction, and in particular, isolated GHD. Growth hormone replacement therapy (GHRT) has long been known to have a beneficial effect on body composition and exercise capacity. However, it has recently been shown that GHRT also benefits the brain. The primary objective of the current study is to assess the effect of GH on memory, executive function and attention domains of cognitive function in GHD- professional football players with TBI. The study will also utilize the adult growth hormone deficiency assessment (AGHDA) questionnaire, quantitative electroencephalogram (QEEG) and magnetic resonance imaging (MRI) techniques, respectively, to measure the quality of life (QoL), electrical activity and structural changes in the brain that may correspond to cognitive deficits.
Patients complete questionnaires over 15-20 minutes and undergo audio recording of clinic conversations between the oncology team or the specialist palliative care team. Patients' medical records are also reviewed.
BACKGROUND: The relationship between gut microbiota and vertigo, specifically Benign Paroxysmal Vertigo (BPV) and Vertigo of Central (VC), remains underexplored.
AIM AND HYPOTHESES: This study aims to investigate the causal relationships between gut microbiota and two types of vertigo, BPV and VC. Additionally, the study seeks to explore the mediation effects of metabolic, inflammatory, and psychological factors on these relationships. We hypothesize that specific taxa of gut microbiota have a causal effect on the risk of developing BPV and VC. The mediation effects of HbA1c, obesity, major depression, and interleukin-18 levels significantly influence the relationships between gut microbiota and vertigo.
METHOD: Utilizing a bidirectional two-sample Mendelian randomization approach, this study investigated causal associations between gut microbiota and the two types of vertigo. A network MR assessed mediation effects of HbA1c, major depression, obesity, and interleukin-18 levels, with data sourced from several consortia, including MiBioGen.
RESULTS: Distinct gut microbiota displayed varying influences on BPV and VC risks. A total of ten taxa affect BPV. Among these, two taxa have an odds ratio (OR) greater than 1, including one class, one order. Conversely, eight taxa have an OR less than 1, encompassing four families, three genera, and one order. The OR for these taxa ranges from 0.693 to 0.930, with p-values between 0.006 and 0.048. For VC, eight taxa were found to have an impact. Five of these taxa exhibit an OR greater than 1, including four genera and one phylum. The OR for these taxa ranges from 1.229 to 2.179, with p-values from 0.000 to 0.046. The remaining three taxa have an OR less than 1, comprising one family and two genera, with an OR range of 0.445 to 0.792 and p-values ranging from 0.013 to 0.050. The mediation analysis for BPV shows that major depression, obesity, and HbA1c are key mediators between specific taxa and BPV. Major depression mediates 28.77% of the effect of family Rhodospirillaceae on BPV. Obesity mediates 13.90% of the effect of class Lentisphaeria/order Victivallales. HbA1c mediates 11.79% of the effect of genus Bifidobacterium, 11.36% of family Bifidobacteriaceae/order Bifidobacteriales. For VC, interleukin-18 levels and major depression are significant mediators. Interleukin-18 levels mediate 6.56% of the effect of phylum Actinobacteria. Major depression mediates 6.51% of the effect of genus Alloprevotella.
CONCLUSION: The study highlights potential causal links between gut microbiota and vertigo, emphasizing metabolic and psychological mediators. These insights underscore the therapeutic potential of targeting gut health in vertigo management.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor containing a solvent-extract of Saxifrage as the active ingredient, showing elastase inhibiting effect, keeping the skin smooth, elastic and vivid, and useful for, e.g. foundations, and make-up, hair and bath cosmetics. SOLUTION: This inhibitor, containing a solvent-extract of Saxifrage as the active ingredient, is obtained by treating the whole body of the above plant with an extraction solvent (e.g. methanol, ethanol and 1,3-butylene glycol) by immersion or heating with reflux, and filtration and enrichment of the effluent. The preparation for external use is incorporated with the extract preferably at 0.001 to 10.0 wt.% (dry basis). The elastase inhibitor, when to be used as an anti-senescence agent, may be incorporated with a skin-whitening agent, humectant, antioxidant, oily ingredient or the like. It may be also incorporated with disodium edetate, sodium citrate or the like. It is preferably used for cosmetics.
Chronic musculoskeletal pain is often associated with lower socioeconomic status (SES). SES correlates with psychological and environmental conditions that could contribute to the disproportionate burden of chronic stress. Chronic stress can induce changes in global DNA methylation and gene expression, which increases risk of chronic pain. We aimed to explore the association of epigenetic aging and SES in middle-to-older age individuals with varying degrees of knee pain. Participants completed self-reported pain, a blood draw, and answered demographic questions pertaining to SES. We used an epigenetic clock previously associated with knee pain (DNAmGrimAge) and the subsequent difference of predicted epigenetic age (DNAmGrimAge-Diff). Overall, the mean DNAmGrimAge was 60.3 (±7.6), and the average DNAmGrimAge-diff was 2.4 years (±5.6 years). Those experiencing high-impact pain earned less income and had lower education levels compared to both low-impact and no pain groups. Differences in DNAmGrimAge-diff across pain groups were found, whereby individuals with high-impact pain had accelerated epigenetic aging (∼5 years) compared to low-impact pain and no pain control groups (both ∼1 year). Our main finding was that epigenetic aging mediated the associations of income and education with pain impact, as such the relationship between SES and pain outcomes may occur through potential interactions with the epigenome reflective of accelerated cellular aging. PERSPECTIVE: Socioeconomic status (SES) has previously been implicated in the pain experience. The present manuscript aims to present a potential social-biological link between SES and pain via accelerated epigenetic aging.
Participants will be paired with a community health worker who will provide tailored support to address unmet social needs. The number and frequency of calls will be limited only by participants' needs, interest, and willingness to interact. The type of contact could include phone calls, or home/community visits. The community health worker will: (1) identify and assess patients' unmet social needs; (2) jointly generate solutions; (3) help prioritize among multiple needs; (4) identify community resources that could help resolve the problem(s); (5) determine eligibility for services; (6) help patients access available resources by scheduling appointments and providing appointment reminders; (7) prepare patients to interact with service agencies and/or act as an advocate; (8) provide support such as arranging transportation; (9) oversee follow-up problem-solving actions; and (10) review progress made towards resolving unmet social needs and adapt solutions.
<P>PROBLEM TO BE SOLVED: To provide a new human CC-chemokine receptor, to provide an antibody against the receptor or an antigenic bonded fragment thereof and to provide a pharmaceutical composition comprising the same.  <P>SOLUTION: A mammalian (e.g. human) CCR2 [CC-chemokine receptor (2)] is isolated and the antibody or the functional fragment thereof which binds to the CCR2 or a portion of the receptor and blocks the binding of a ligand to the receptor is isolated. Furthermore, a method for inhibiting an interaction of a cell bearing the mammalian CCR2 with a ligand thereof is provided. The use of the antibody and fragment in prophylactic and diagnostic methods is provided.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Cisplatin-based chemotherapy (Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Cisplatin was done for 3 cycles with 30 days after last surgery.
Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
BACKGROUND: DNA repair mechanisms are essential for tumorigenesis and disruption of HR mechanism is an important predisposing factor of human breast cancers (BC). PALB2 is an important part of the HR. There are similarities between canine mammary tumours (CMT) and BCs. As its human counterpart, PALB2 mutations could be a predisposing factor of CMT.
OBJECTIVES: In this study, we aimed to investigate the impacts of PALB2 variants on tumorigenesis and canine mammary tumor (CMT) malignancy.
METHODS: We performed Sanger sequencing to detect germline mutations in the WD40 domain of the canine PALB2 gene in CMT patients. We conducted in silico analysis to investigate the variants, and compared the germline PALB2 mutations in humans that cause breast cancer (BC) with the variants detected in dogs with CMT.
RESULTS: We identified an intronic (c.3096+8C>G) variant, two exonic (p.A1050V and p.R1354R) variants, and a 3' UTR variant (c.4071T>C). Of these, p.R1354R and c.4071T>C novel variants were identified for the first time in this study. We found that the p.A1050V mutation had a significant effect. However, we could not determine sufficient similarity due to the differences in nucleotide/amino acid sequences between two species. Nonetheless, possible variants of human sequences in the exact location as their dog counterparts are associated with several cancer types, implying that the variants could be crucial for tumorigenesis in dogs. Our results did not show any effect of the variants on tumor malignancy.
CONCLUSIONS: The current project is the first study investigating the relationship between the PALB2 gene WD40 domain and CMTs. Our findings will contribute to a better understanding of the pathogenic mechanism of the PALB2 gene in CMTs. In humans, variant positions in canines have been linked to cancer-related phenotypes such as familial BC, endometrial tumor, and hereditary cancer predisposition syndrome. The results of bioinformatics analyses should be investigated through functional tests or case-control studies.
BACKGROUND: Scapular notching is a common complication of reverse total shoulder arthroplasty (RTSA). Although the notching rate has reduced significantly thanks to modifications to the surgical technique and humeral and glenoid components, uncontrollable polyethylene (PE)-induced osteolysis can still occur. In contrast to conventional-bearing (CB-RTSA), inverted-bearing RTSA (IB-RTSA) systems, with PE glenospheres and metal or ceramic humeral liners, avoid PE abrasion through scapulohumeral contact. If present, the resulting notch has a different size and configuration than with CB-RTSA. Thus, a modified notching classification seems reasonable. Even in CB-RTSA, the early stages of notching show a different configuration than implied by the established Nerot-Sirveaux classification; therefore, a modification of the classification system is recommended.
METHODS: In a prospective multicentre study, 250 cases underwent IB-RTSA. Of these, 39 died, and 28 were lost to follow-up for other reasons, leaving 183 shoulders for the final follow-up examination at a mean of 120.7 months (range 84.1-172.4 months). In the CB-RTSA group, we retrospectively evaluated radiographs of 59 consecutive patients with a follow-up ranging from 2 to 7 years. We analysed the appearance, evolution over time, and location of bone loss on the scapular neck according to the modified Nerot-Sirveaux classification.
RESULTS: In IB-RTSA, notching resulted in a new morphological configuration: In contrast to the Nerot-Sirveaux classification, notching began far from the baseplate as an impression or abrasion of the humeral component in the inferior scapular rim. Due to simultaneous mechanical ablation, the defect gradually enlarged, but usually did not contact the baseplate or extend beyond the inferior peg. No signs of PE-induced osteolysis were found. The notching rate reached 19% after 2 years and approached 36% after 10 years. Most shoulders had grade 0 notching (64%), followed by grade 1 (29%); extensive erosion (grade 4) was not observed. In the CB-RTSA group, a small bony impression or erosion without signs of PE-induced osteolysis was observed medial to the scapular neck, without contact with the metaglene in the early phase, which was similar to the impression of the humeral component in IB-RTSA. The notching rate was 86% for CB-RTSA.
CONCLUSIONS: A new classification was developed for IB-RTSA, which corresponds to the pathophysiological processes and is compatible with the existing Nerot-Sirveaux classification. Bone erosion in CB-RTSA is not adequately represented by the established classification in the early stages. For this reason, a supplement to the existing classification is presented.
LEVEL OF EVIDENCE: Level 4, Case Series, Treatment Study.
Low back pain affects about 60% to 90% of the working-age population in modern industrial society. Chronic mechanical low back pain (CMLBP) is the most common problem of the working-age population in modern industrial society; it causes a substantial economic burden due to the wide use of medical services and absence from work. The purpose of this trial was to evaluate the short-term effect of acupuncture dry needle in treatment of chronic mechanical low back pain. Thirty patients their age ranged from 20 - 45 years participated in our study and divided randomly into two equal groups suffering from nonspecific low back pain. The first group (A) consist of 15 patients receiving acupuncture dry needle over trigger points of back muscles followed by stretching and strengthening exercises for back muscles, the second group (B) consist of 15 patients receiving only stretching and strengthening exercises for back muscles. The following parameters including pain severity, functional disability and lumbar range of motion (flexion, extension, right side bending and left side bending) were measured before and after treatment.
PURPOSE:A secretin-containing composition useful as a remedy for pancreatic or cystic diseases, having enhanced promoting action of secretin on secretion of pancreatic juice, prolonging the action, obtained by blending secretin with sodium benzoate as an essential component. CONSTITUTION:Secretin is blended with sodium benzoate, to give a secretin-containing composition having enhanced action. An amount of sodium benzoate blended is preferably 1-15% W/W. Especially, when the composition is a suppository, the amount is 10% W/W and, when it is an injection, the amount is properly 2-4%. A dosage form of administration is not limited, especially suppository or injection is preferable. In the case of suppository, preferably sodium benzoate is precoated with wax (e.g., carnauba wax) and used. In the case of rectum administration or injection administration, it is based on information that promoting action of serectin on secretion of pancreatic juice is enhanced by the addition of sodium benzoate.
Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks for 3 cycles, then undergo surgery within 3 weeks. Within 84 days, patients receive pembrolizumab IV over 30 minutes every 3 weeks for 15 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.
BACKGROUND: Previous studies have established a connection between Hashimoto's thyroiditis (HT) and an increased risk of papillary thyroid carcinoma (PTC). However, the molecular mechanisms driving this association are not well understood. The long non-coding RNA (lncRNA) BRAF-activated non-coding RNA (BANCR) has been implicated in various cancers, suggesting a potential role in the HT-PTC linkage.
METHODS: This study investigated the expression levels of BANCR in PTC and HT samples, compared to control tissues. We also examined the association between BANCR expression and clinicopathological features, including lymph node metastasis. Furthermore, we explored the molecular mechanisms of BANCR in PTC pathogenesis and its potential as a therapeutic target.
RESULTS: BANCR expression was significantly lower in PTC samples than in controls, while it was moderately increased in HT samples. In PTC cases with concurrent HT, BANCR expression was markedly reduced compared to normal tissues. Our analysis revealed BANCR's role as an oncogene in PTC, influencing various cancer-related signaling pathways. Interestingly, no significant correlation was found between BANCR expression and lymph node metastasis.
CONCLUSION: Our findings underscore the involvement of BANCR in the connection between HT and PTC. The distinct expression patterns of BANCR in PTC and HT, especially in PTC with concurrent HT, provide new insights into the molecular interplay between these conditions. This study opens avenues for the development of innovative diagnostic and therapeutic strategies targeting BANCR in PTC and HT.
PURPOSE:To obtain an enzyme-containing cleansing powder exhibiting excellent cleansing effect by the enzyme, by using a microorganism-originated enzyme, an animal-originated enzyme and a vegetable-originated enzyme together with a surfactant as a cleansing agent and adding the agent to a base such as corn starch, talc, etc. CONSTITUTION:An enzyme-containing cleansing powder can be produced by compounding a base such as corn starch, talc, etc., with a cleansing agent consisting of a surfactant, a microorganism-originated enzyme (enzyme having proteolytic activity, etc., and obtained from Bacillus subtilis, Aspergillus oryzae, Actinomycete, etc.), an animal-originated enzyme (enzyme having proteolytic activity, lypolytic activity, amylolytic activity, etc., and obtained from animal organ, e.g. pancreatin) and a vegetable-originated enzyme (papain, ficin, bromelain, etc., or an enzyme having proteolytic activity, lypolytic activity, amylolytic activity, etc., obtained from soybean, malt, etc.) and preferably adding sodium polyacrylate to the composition. The enzyme is stabilized by granulation.
This investigation is undertaken to evaluate the workflow and concomitant products to create full dentures by using additive manufacturing (AM) technology, i.e. Digital Light Processing™ Technology (Carbon 3D) to restore fully edentulous jaws. The assessment includes quality of materials provided by Dentsply Sirona Lab by using printers for AM (M series, Carbon 3D 1089 Mills Way, Redwood City, CA 94063). This assessment will be done by clinical review of the AM dentures on fit and quality. In addition, the evaluation includes a patient survey to assess current dentures and the new AM dentures with a subjective comparison of both.

The target subjects are male or female, 18 years and older with the need of a full denture in one or both jaws, being completely edentulous. The newly fabricated denture is to replace an existing full denture. For this descriptive study, no minimum number of patients is defined, but to achieve a reasonable subject number, a minimum of five (5) and a maximum of ten (10) patients will be enrolled, i.e. ten to twenty (10-20) denture arches will be fabricated within this study.